We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

ORASURE TECHNOLOGIES

OraSure Technologies develops, manufactures and distributes oral fluid diagnostic and collection devices and other te... read more Featured Products: More products

Download Mobile App




New Rapid Ebola Antigen Test Detects Infection at Point of Care

By LabMedica International staff writers
Posted on 23 Jul 2026

A serious Ebola epidemic centered in the Democratic Republic of the Congo has caused hundreds of deaths and triggered a global public health emergency, with cases also reported in Uganda. More...

Rapid diagnosis is critical, including confirmation in recently deceased individuals, but response efforts are complicated by the Bundibugyo virus, which has no approved vaccine or targeted treatment. A newly authorized rapid antigen test now supports time-critical detection at or near the point of care, delivering results in 30 minutes.

OraSure Technologies' OraQuick Ebola 2.0 Rapid Antigen Test has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for use with whole blood from living patients and cadaveric oral fluid from individuals suspected of having Ebola disease at the time of death. The second‑generation assay detects all four Ebola viruses known to cause human disease: Bundibugyo, Zaire, Sudan, and Taï Forest. The authorization encompasses use in symptomatic individuals with known risk factors and in the deceased to guide safe handling and burial.

The test is a single‑use, qualitative immunoassay that detects antigens from viruses within the Orthoebolavirus genus, though it does not differentiate between specific Ebola viruses. Results are read directly on the device at 30 minutes without instruments, batteries, smartphones, or laboratory analysis. The format is designed to support rapid triage and infection control in resource‑constrained or decentralized settings.

OraQuick Ebola 2.0 follows the company’s first‑generation OraQuick Ebola Rapid Antigen Test, which received De Novo marketing authorization in 2019 as the first and only rapid antigen test with full authorization for Ebola virus detection. The new version incorporates increased sensitivity, a new assay chemistry, and a more automated manufacturing process. 

The ongoing Ebola outbreak, concentrated in the Democratic Republic of the Congo and spreading into neighboring Uganda, has caused hundreds of deaths and led the World Health Organization to declare a global public health emergency. In response, the company is increasing production of the OraQuick Ebola 2.0 Rapid Antigen Test to address potential demand and broaden access to a reliable, proven diagnostic tool.

“We are proud to advance a second-generation Ebola test at a time when the world is confronting a serious and evolving outbreak in Central Africa. This outbreak is particularly challenging due to the Bundibugyo virus, which has no approved vaccine or targeted treatment, reinforcing the critical need for rapid, accurate diagnostics that can detect this virus and support timely containment efforts,” said Carrie Eglinton Manner, President and CEO of OraSure.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Blood Protein Analysis Reveals Menopause-Associated Signals of Brain Aging

Menopause affects women across midlife and is often accompanied by endocrine changes, hot flashes, brain fog and sleep disturbances. Women spend roughly one third of their lives after the menopause transition,... Read more

Molecular Diagnostics

view channel
Image:(L to R) Co-first author Yuan Feng, PhD, corresponding author Xiaotu Ma, PhD, and co-first author Hanxia Li, PhD, all of the St. Jude Department of Computational Biology. (Photo courtesy of St. Jude Children\'s Research Hospital)

Genomic Profiling Predicts Relapse Risk by Subtype in Pediatric Leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with more than 90% of patients surviving with modern treatments. Outcomes are worse when the disease returns, however, making... Read more

Hematology

view channel
Image: The newly certified products are the CytoCell ATM Deletion FISH Probe, CytoCell IGH Plus Breakapart FISH Probe, CytoCell IGH/FGFR3 Plus Translocation, Dual Fusion FISH Probe, and CytoCell IGH/MYEOV Plus Translocation, Dual Fusion FISH Probe. (Photo courtesy of OGT)

Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers

Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more

Immunology

view channel
Image: Study design and collection of lower respiratory tract lining fluid (RTLF) using the PExA instrument. (Aguilera K, Hober A, Greilert Norin N, et al. eBioMedicine, 2026. doi:10.1016/j.ebiom.2026.106538)

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The acquisition of Proscia advances Agilent’s efforts to expand its pathology portfolio and strengthens its competitive position in a rapidly growing market.

Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia

Agilent Technologies has completed its acquisition of Proscia, a provider of digital pathology software for clinical and life sciences applications. The transaction involved a cash payment of USD 240 million... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.